---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-033498"
form_type: "8-K"
ticker: "MTNB"
cik: "0001582554"
company_name: "Matinas BioPharma Holdings, Inc."
filed_at: "2023-09-22T23:59:59+00:00"
generated_at: "2026-06-10T09:40:42.371635+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Matinas BioPharma receives NYSE American deficiency notice for low price; must cure by Mar 2024

## Summary
- Received NYSE American deficiency letter for non-compliance with Section 1003(f)(v) due to 30-day avg closing price below $0.20.
- Must demonstrate sustained price improvement or effect reverse stock split by March 21, 2024 to regain compliance.
- Common stock continues trading on NYSE American under symbol MTNB; no immediate delisting.
- Company is actively engaging with Exchange and developing plans to cure within the cure period.

## SEC filing metadata
- accession: 0001493152-23-033498
- form_type: 8-K
- ticker: MTNB
- cik: 0001582554
- company_name: Matinas BioPharma Holdings, Inc.
- filed_at: 2023-09-22T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582554/000149315223033498/0001493152-23-033498-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582554/000149315223033498/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-033498
- JSON: https://secwatch.observer/filing/0001493152-23-033498.json
- Plain text: https://secwatch.observer/filing/0001493152-23-033498.txt

## Key facts
- Listing & Compliance Notices
  Matinas BioPharma Holdings, Inc. received a nyse_american deficiency notice notice regarding minimum bid price (rules 1003(f)(v), 1009).
  - Exchange: nyse american
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 1003(f)(v), 1009
  source text: September 21, 2023, Matinas Biopharma Holdings, Inc. (the “Company”) received a deficiency letter (the “Letter”) from the NYSE American LLC (the “NYSE American” or the “Exchange”) indicating that the Company is not in compliance with the NYSE American continued listing standard set forth in Section 1003(f)(v) of the NYSE American Company Guide due to its shares of common stock selling for a substantial period of time at a low price per share, which NYSE American determined to be a 30 trading day average price of less than $0.20 per share. The Letter has no immediate effect on the listing or tr
  evidence_url: https://www.sec.gov/Archives/edgar/data/1582554/000149315223033498/0001493152-23-033498-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.